Provided by Tiger Trade Technology Pte. Ltd.

Leap Therapeutics Inc

2.05
0.0000
Volume:- -
Turnover:1.04B
Market Cap:116.14M
PE:-1.28
High:2.05
Open:2.05
Low:2.05
Close:2.05
52wk High:3.61
52wk Low:0.2223
Shares:56.65M
Float Shares:49.88M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.6003
EPS(LYR):-1.8115
ROE:-183.72%
ROA:-77.23%
PB:20.31
PE(LYR):-1.13

Loading ...

Company Profile

Company Name:
Leap Therapeutics Inc
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
- -
Office Location:
- -
Zip Code:
- -
Phone:
- -
Fax:
- -
Introduction:
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase I clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.